Friday, January 19, 2024 4:36:00 PM
I think any of us that know this industry already have the answers to these questions. DCVax and NW Bio will not remain independent long enough for any of this to happen under the current Management Team. It will be sold, friendly or hostile. That is pretty much a given.
This all has to be proven, with trials, trials and more trials. In order to expand the technology beyond GBM it will cost $Billions and take another 7-10 years. If you know this industry well, you should know how many road-blocks that exist at every turn, in the most regulated space any company has to operate in. You are also assuming a better technology and competition doesn't exist. Rest assured it does. What is new and shiny today could be old and rusted tomorrow. Science is moving faster that at any point in time.
Once again, we are years and years and $Billions away from any of this. It also hasn't been proven in other indications until a trial is run and results are reviewed and determined a success or failure. You are putting the cart before the horse. I am long and own way too many shares, but a lot of what you say is based on opinion, not fact. The only facts we have that can be vetted via a marketing application and approval is with GBM. All other indications are speculation at this point. Trust me, the FDA just wont take your word for it ;) This is fact.
Its pretty easy to put a valuation on DCVax at this point: $15-25B based off what we know today and the numbers for treating GBM worldwide, not tomorrow or 10 years from now.
Recent NWBO News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM